Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines

Cancer Letters

Volumn 278, Issue 1, 2009, Pages 49-55

  Kai, Kiyonori ^a,c   D'Costa, Susan ^a   Sills, Robert C ^b   Kim, Yongbaek ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

AG1024; Chemoresistance; Cisplatin; Insulin like growth factor 1 receptor; Malignant mesothelioma

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; CISPLATIN; PROTEIN P42; PROTEIN P44; SOMATOMEDIN C RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TYRPHOSTINS;

EID: 63449104490     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.023     Document Type: Article

References (33)

1. Britton M. The epidemiology of mesothelioma. Semin. Oncol. 29 (2002) 18-25
2. Bielefeldt-Ohmann H., Jarnicki A.G., and Fitzpatrick D.R. Molecular pathobiology and immunology of malignant mesothelioma. J. Pathol. 178 (1996) 369-378
3. Sun X., Wei L., Liden J., Hui G., Dahlman-Wright K., Hjerpe A., and Dobra K. Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J. Pathol. 207 (2005) 91-101
4. Whitson B.A., and Kratzke R.A. Molecular pathways in malignant pleural mesothelioma. Cancer Lett. 239 (2006) 183-189
5. Fennell D.A., Gaudino G., O'byrne K.J., Mutti L., and Van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat. Clin. Pract. Oncol. 5 (2008) 136-147
6. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
7. Hengstler J.G., Lange J., Kett A., Dornhofer N., Meinert R., Arand M., Knapstein P.G., Becker R., Oesch F., and Tanner B. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res. 59 (1999) 3206-3214
8. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
9. Winograd-Katz S.E., and Levitzki A. Cisplatin induces PKB/Akt activation and p38 (MAPK) phosphorylation of the EGF receptor. Oncogene 25 (2006) 7381-7390
10. Lee M.W., Kim D.S., Min N.Y., and Kim H.T. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int. J. Cancer 122 (2008) 2380-2384
11. Belyanskaya L.L., Hopkins-Donaldson S., Kurtz S., Simoes-Wust A.P., Yousefi S., Simon H.U., Stahel R., and Zangemeister-Wittke U. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int. J. Cancer 117 (2005) 755-763
12. Wang Z., Xu J., Zhou J.Y., Liu Y., and Wu G.S. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res. 66 (2006) 8870-8877
13. Wang X., Martindale J.L., and Holbrook N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275 (2000) 39435-39443
14. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev. 17 (2006) 305-323
15. Kurmasheva R.T., and Houghton P.J. IGF-I mediated survival pathways in normal and malignant cells. Biochim. Biophys. Acta 1766 (2006) 1-22
16. Hartog H., Wesseling J., Boezen H.M., and Van Der Graaf W.T. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur. J. Cancer. 43 (2007) 1895-1904
17. Porcu P., Ferber A., Pietrzkowski Z., Roberts C.T., Adamo M., Leroith D., and Baserga R. The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulin like growth factor 1 with its receptor. Mol. Cell. Biol. 12 (1992) 5069-5077
18. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267 (1995) 1782-1788
19. Parrizas M., Gazit A., Levitzki A., Wertheimer E., and Leroith D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138 (1997) 1427-1433
20. Manfredi J.J., Dong J., Liu W.J., Resnick-Silverman L., Qiao R., Chahinian P., Saric M., Gibbs A.R., Phillips J.I., Murray J., Axten C.W., Nolan R.P., and Aaronson S.A. Evidence against a role for SV40 in human mesothelioma. Cancer Res. 65 (2005) 2602-2609
21. Hoang C.D., Zhang X., Scott P.D., Guillaume T.J., Maddaus M.A., Yee D., and Kratzke R.A. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res. 64 (2004) 7479-7485
22. Riedemann J., and Macaulay V.M. IGF1R signalling and its inhibition. Endocr. Relat. Cancer 13 Suppl. 1 (2006) S33-S43
23. Camirand A., Zakikhani M., Young F., and Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res. 7 (2005) R570-579
24. Von Willebrand M., Zacksenhaus E., Cheng E., Glazer P., and Halaban R. The tyrphostin AG1024 accelerates the degradation of phosphorylated forms of retinoblastoma protein (pRb) and restores pRb tumor suppressive function in melanoma cells. Cancer Res. 63 (2003) 1420-1429
25. Page C., Lin H.J., Jin Y., Castle V.P., Nunez G., Huang M., and Lin J. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 20 (2000) 407-416
26. Mccubrey J.A., Steelman L.S., Abrams S.L., Lee J.T., Chang F., Bertrand F.E., Navolanic P.M., Terrian D.M., Franklin R.A., D'assoro A.B., Salisbury J.L., Mazzarino M.C., Stivala F., and Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46 (2006) 249-279
27. Wu H., Cao Y., Weng D., Xing H., Song X., Zhou J., Xu G., Lu Y., Wang S., and Ma D. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett. 271 (2008) 260-271
28. Lee S., Choi E.J., Jin C., and Kim D.H. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol. Oncol. 97 (2005) 26-34
29. Lackey J., Barnett J., Davidson L., Batty I.H., Leslie N.R., and Downes C.P. Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling. Oncogene 26 (2007) 7132-7142
30. Feng Z., Hu W., De Stanchina E., Teresky A.K., Jin S., Lowe S., and Levine A.J. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67 (2007) 3043-3053
31. Yi H.K., Kim S.Y., Hwang P.H., Kim C.Y., Yang D.H., Oh Y., and Lee D.Y. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. Biochem. Biophys. Res. Commun. 330 (2005) 760-767
32. Mutti L., and Broaddus V.C. Malignant mesothelioma as both a challenge and an opportunity. Oncogene 23 (2004) 9155-9161
33. Boulikas T., and Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol. Rep. 10 (2003) 1663-1682